May 27, 2019
MSD K.K., the Japan arm of US Merck, has been unable to launch its broad-spectrum antibiotic injection Zerbaxa (ceftolozane and tazobactam) in the market three months after its reimbursement listing as it finds it difficult to ensure the drug’s stable...read more